TR200201081A3 - Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari - Google Patents

Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari

Info

Publication number
TR200201081A3
TR200201081A3 TR2002/01081A TR200201081A TR200201081A3 TR 200201081 A3 TR200201081 A3 TR 200201081A3 TR 2002/01081 A TR2002/01081 A TR 2002/01081A TR 200201081 A TR200201081 A TR 200201081A TR 200201081 A3 TR200201081 A3 TR 200201081A3
Authority
TR
Turkey
Prior art keywords
mutants
weakened
rabies virus
live vaccines
recombinant rabies
Prior art date
Application number
TR2002/01081A
Other languages
English (en)
Other versions
TR200201081A2 (tr
Inventor
Mebatsion Teshome
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of TR200201081A2 publication Critical patent/TR200201081A2/tr
Publication of TR200201081A3 publication Critical patent/TR200201081A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TR2002/01081A 2001-04-23 2002-04-19 Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari TR200201081A3 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201464 2001-04-23
EP01203773 2001-10-05

Publications (2)

Publication Number Publication Date
TR200201081A2 TR200201081A2 (tr) 2002-11-21
TR200201081A3 true TR200201081A3 (tr) 2002-11-21

Family

ID=26076884

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01081A TR200201081A3 (tr) 2001-04-23 2002-04-19 Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari

Country Status (10)

Country Link
US (1) US6887479B2 (tr)
EP (1) EP1253197B1 (tr)
AR (1) AR033873A1 (tr)
AT (1) ATE316572T1 (tr)
BR (1) BR0201366A (tr)
CA (1) CA2382993A1 (tr)
DE (1) DE60208854T2 (tr)
ES (1) ES2257505T3 (tr)
PT (1) PT1253197E (tr)
TR (1) TR200201081A3 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695724B2 (en) * 2004-07-12 2010-04-13 Thomas Jefferson University Recombinant rabies virus compositions
CN101287838B (zh) 2005-10-14 2016-03-30 美国政府健康及人类服务部，疾病控制和预防中心 狂犬病病毒组合物和方法
US20100278864A1 (en) * 2005-12-14 2010-11-04 University Of Georgia Research Foundation, Inc. Rabies Vaccine
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
CN103068985A (zh) 2010-06-24 2013-04-24 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 抗狂犬病的广谱狂犬病病毒属病毒疫苗
EP2670843B1 (en) 2011-02-03 2014-10-29 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Multivalent vaccines for rabies virus and filoviruses
EP4104854A3 (en) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032755A1 (en) * 1998-11-27 2000-06-08 Akzo Nobel N.V. Stable, attenuated rabies virus mutants and live vaccines thereof

Also Published As

Publication number Publication date
CA2382993A1 (en) 2002-10-23
TR200201081A2 (tr) 2002-11-21
AR033873A1 (es) 2004-01-07
BR0201366A (pt) 2003-06-10
US20020164356A1 (en) 2002-11-07
DE60208854T2 (de) 2006-08-17
ES2257505T3 (es) 2006-08-01
US6887479B2 (en) 2005-05-03
PT1253197E (pt) 2006-06-30
EP1253197A1 (en) 2002-10-30
ATE316572T1 (de) 2006-02-15
DE60208854D1 (de) 2006-04-13
EP1253197B1 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
AU2003235707A8 (en) Immunogenic preparations and vaccines on the basis of mrna
NO20020400L (no) Sekvenser og metoder for deteksjon av hepatitt C virus
ITMI20022775A1 (it) Circuito e procedimento di post-riparazione di
FR14C0016I2 (fr) Vacccin west nile
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
AU4932601A (en) Recombinant parainfluenza virus expression systems and vaccines
NO20030239L (no) Modifisert virus
TR200201081A3 (tr) Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
EP1651258A4 (en) HEPATITIS VIRUS CORE PROTEINS AS VACCINE PLATFORMS AND USE THEREOF
NO20033829L (no) Virusdrepende preparater
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
DE60226057D1 (de) Geflügelkrankheit verursachendes bakterium und daraus stammender impfstoff
ATE356202T1 (de) Attenuierte stabile tollwutvirusmutante und lebende impfstoffe
NO20020399D0 (no) Sekvenser og fremgangsmåter for påvisning av hepatitt B-virus
AU2003287216A8 (en) Gb virus c and methods of treating viral infections
IS2797B (is) Bóluefni gegn ISA-veiru
IL149173A0 (en) Attenuated recombinant rabies virus mutants and live vaccines thereof
IL161022A0 (en) Methods of treating liver fibrosis and hepatitis c virus infection
FR2823218B1 (fr) Souche neurovirulente du virus west nile et ses applications
DE60124313D1 (de) Dns-vakzine von hypervariablen vh-cdr3 idiotypischen determinanten
IS5778A (is) Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar
FR2829149B1 (fr) Souche neurovirulente du virus west nile et ses applications